Balaji Amines Limited (BALAMINES) AI Stock Analysis

• Market Cap: ₹37.71B
• Dividend Yield: 0.97%
• Average Volume (3M): 3.13K
• Price to Earnings (P/E): 25.9
• Beta (1Y): 1.24
• Revenue Growth: -10.76%
• EPS Growth: -27.70%
• Country: IN
• Employees: 1,084
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 10.20
• Shares Outstanding: 32,401,000
• 10 Day Avg. Volume: 2,179
• 30 Day Avg. Volume: 3,132
• PEG Ratio: -1.11
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 2.91
• P/FCF Ratio: 46.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ₹1,339.00 ▲(22.75% Upside)

The score is driven primarily by strong financial quality (low leverage and positive free cash flow), partially offset by mixed technicals (negative MACD and below longer-term moving averages) and a middling valuation (P/E 27.17 with a low ~0.90% dividend yield).

Positive Factors

Strong balance sheet / low leverage

A low debt-to-equity profile and robust equity ratio provide durable financial flexibility. This supports capital spending, cushions cyclical downturns in chemicals demand, and allows the company to fund R&D or strategic projects without relying heavily on external financing.

Positive free cash flow and cash conversion

Consistent positive free cash flow and healthy cash conversion underpin self-funded growth capacity. This strengthens the firm's ability to invest in capacity, maintain plant reliability, and support product development while minimizing dependence on costly external capital.

Diversified end-market exposure

Serving pharmaceuticals, agrochemicals and personal care creates structural demand diversification. Exposure to these resilient, growing end markets reduces single-sector cyclicality, helping stabilize sales over business cycles and supporting long-term product demand visibility.

Negative Factors

Recent revenue and EPS contraction

Double-digit revenue decline and large EPS fall signal weakening demand or margin pressure. Persistent top-line and earnings deterioration can erode reinvestment capacity, strain working capital, and force trade-offs between margins, capex and R&D, hampering medium-term growth.

Income statement showing recent contraction

Even with historically stable gross and net margins, contracting revenue and net income reduce operating leverage benefits. If growth does not resume, fixed-cost absorption worsens, pressuring margins and limiting funds for strategic investments or margin-improvement initiatives.

Product concentration in amines

Heavy reliance on amines and a few core products creates concentration risk. Feedstock price swings, regulatory changes or demand shifts in core applications could disproportionally impact revenues, limiting resilience and constraining diversification of long-term growth streams.

Balaji Amines Limited Business Overview & Revenue Model

Company Description

Balaji Amines Limited engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India. The company operates through three segments: Amines & Speciality Chemicals, Hotel, and CFL Lamps. It offers monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, dimethyl and diethyl amino ethanol; and specialty chemicals, including N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. The company also provides derivatives comprising di-methyl acetamide, di-methyl amine hydrochloride, tri-methyl amine hydrochloride, di-ethyl amine hydrochloride, tri-ethyl amine hydrochloride, di-methyl urea, and choline chloride; and pharma excipients, such as poly vinyl pyrrolidone. It serves pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning chemical, dye and textile, and water treatment chemical industries. In addition, the company operates Balaji Sarovar, a hotel in Solapur, Maharashtra; and manufactures and sells CFL lamps. It also exports its products to the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and internationally. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Balaji Amines generates revenue through the production and sale of its specialty chemicals, particularly amines and their derivatives. The company has established a strong revenue model based on a diverse customer base spanning multiple industries, including pharmaceuticals, agrochemicals, and personal care. Key revenue streams include the sale of high-demand products such as methylamines and ethylamines, which are utilized in numerous applications from drug manufacturing to agricultural chemicals. Additionally, BALAMINES benefits from long-term partnerships with major players in its target sectors, ensuring consistent demand for its products. The company also focuses on research and development to innovate and expand its product offerings, further enhancing its market position and revenue potential.

Balaji Amines Limited Financial Statement Overview

Summary

Balaji Amines demonstrates strong financial health with a stable balance sheet and consistent cash flow generation. Despite revenue pressures, the company maintains profitability, indicating good operational efficiency. However, addressing revenue challenges is crucial for long-term growth.

Income Statement

Balaji Amines has shown resilience in its income statement despite revenue fluctuations. The Gross Profit Margin and Net Profit Margin have been reasonably stable, reflecting effective cost management. However, the recent contraction in revenue and net income suggests challenges in market conditions or competition.

Balance Sheet

The balance sheet is strong, with a low Debt-to-Equity Ratio indicating conservative financial leverage. The equity ratio is robust, showcasing a solid capital structure. However, the company should watch for any increase in liabilities that could affect its financial stability.

Cash Flow

Cash flow metrics reveal effective cash management, with positive Free Cash Flow indicating the ability to sustain operations and investments. While the Operating Cash Flow to Net Income ratio is healthy, the company must focus on improving cash flow growth to support future expansions.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.71B	13.97B	16.08B	23.38B	23.20B	13.11B
Gross Profit	5.59B	4.88B	3.50B	8.39B	8.57B	5.39B
EBITDA	2.55B	2.65B	3.53B	6.24B	6.36B	3.79B
Net Income	1.52B	1.58B	2.05B	3.26B	3.68B	2.38B
Balance Sheet
Total Assets	0.00	22.52B	21.46B	19.63B	18.75B	13.10B
Cash, Cash Equivalents and Short-Term Investments	3.50B	3.50B	3.31B	3.09B	515.37M	173.23M
Total Debt	0.00	110.27M	196.97M	575.74M	1.01B	1.27B
Total Liabilities	-20.18B	2.34B	2.53B	2.65B	5.60B	4.00B
Stockholders Equity	20.18B	18.45B	17.22B	15.54B	12.50B	8.94B
Cash Flow
Free Cash Flow	0.00	874.82M	704.14M	2.62B	842.07M	-221.07M
Operating Cash Flow	0.00	2.73B	3.34B	3.82B	2.32B	1.10B
Investing Cash Flow	0.00	-1.61B	-1.64B	-1.86B	-1.47B	-615.89M
Financing Cash Flow	0.00	-447.73M	-749.66M	-812.33M	-565.13M	-374.51M

Balaji Amines Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1090.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAMINES, the sentiment is Neutral. The current price of 1090.8 is below the 20-day moving average (MA) of 1115.47, below the 50-day MA of 1182.84, and below the 200-day MA of 1400.49, indicating a neutral trend. The MACD of -10.08 indicates Negative momentum. The RSI at 54.02 is Neutral, neither overbought nor oversold. The STOCH value of 48.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BALAMINES.

Balaji Amines Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	70 Outperform	₹31.34B	22.93	―	0.09%	15.47%	-1.72%
BALAMINES	69 Neutral	₹37.71B	25.86	―	0.97%	-10.76%	-27.70%
ANURAS	66 Neutral	₹148.15B	95.37	―	0.06%	69.32%	113.55%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ALKYLAMINE	61 Neutral	₹79.67B	43.73	―	0.62%	3.95%	8.28%
NEOGEN	54 Neutral	₹29.96B	115.01	―	0.09%	8.44%	-35.59%
FAIRCHEMOR	47 Neutral	₹9.29B	153.43	―	1.07%	-22.10%	-85.56%

Balaji Amines Limited Corporate Events

Balaji Amines Reschedules Q2FY26 Earnings Call

Balaji Amines Limited has announced a change in the schedule for its investor conference call to discuss the Q2 and H1FY26 financial results. Originally planned for 4:00 PM IST, the call has been rescheduled to 12:30 PM IST on the same day, November 12, 2025. This adjustment reflects the company’s proactive approach to engaging with stakeholders and ensuring timely communication of its financial performance.

Balaji Amines Clarifies Misleading Article on Chemical Production

Balaji Amines Limited has issued a clarification regarding a defamatory article published in the Economic Times, which falsely accused the company of producing pharmaceutical-grade chemicals without a license. The company refutes these claims, stating that they only manufacture technical and food grade Propylene Glycol and have not supplied any pharmaceutical-grade products. Balaji Amines emphasizes their commitment to transparency and compliance with regulations, noting that there is no ongoing investigation by Indian authorities as suggested in the article.